Gujarat Alkalies & Chemicals Q4 FY26: The Caustic Trap Sprung

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

The tide is turning, but the boat still leaks.

Gujarat Alkalies swung to a ₹15 crore net profit in Q4 FY26 from three years of losses that left reserves ₹500 crore lighter. Revenue sits at ₹4,358 crore for the full year—respectable growth at 7% YoY—yet operating margins are stuck at 9%, half of what management once routinely delivered. The market pays 0.88x book value here. The company holds ₹171 crore in cash, ₹575 crore in debt, and a ROCE of just 1.4%.

What went wrong? The chlor-alkali industry got hammered. When the unit realisation (ECU)—the weighted average price of caustic soda, chlorine, and hydrogen—crashed, GACL’s earnings collapsed faster than a bank run. FY24 saw operating profit shrink to ₹32 crore from ₹949 crore the year before.

Now ECU is healing. Q4 volumes ticked. The board approved a ₹67 crore hydrogen peroxide plant and a ₹250 crore credit line. But the balance sheet still whispers a hard truth: a business that once averaged 20% margins now struggles to defend single digits. The question isn’t whether it recovers—it’s whether investors will pay full price before proof arrives.

2. Introduction

GACL was born in 1973, backed by the Government of Gujarat, and spent four decades building a near-monopoly on India’s chlor-alkali supply chain. Today it runs two Vadodara plants and two Dahej units. It manufactures 36 products: caustic soda (44% of revenue), chloromethanes (10%), caustic potash (7%), phosphoric acid (7%), and a long tail of specialty chemicals for textiles, soaps, detergents, and water treatment.

The company once owned the game. In FY23, it logged ₹949 crore in operating profit on ₹4,517 crore of revenue. The operating margin was 21%. EPS ran at ₹55.78.

Then came FY24. Caustic prices tanked. Chlorine went negative. The ECU realisation fell from ₹38,401 per metric tonne in FY23 to ₹27,242 in FY24. The company booked a net loss of ₹237 crore. The board cut the dividend to near-zero.

FY25 was a held breath. ECU recovered to ₹31,923 per MT. But that still undershot pre-crisis levels. Operating profit climbed back to ₹279 crore. Net losses narrowed to ₹65 crore, then ₹2 crore by FY26.

Q4 FY26 finally turned positive. Net profit of ₹15 crore. Operating margin of 10% in that quarter alone.

The sector is cyclical. GACL got trapped in the downswing. Now it’s climbing out. Whether it stays out is the story.

3. Business Model: WTF Do They Even Do?

GACL runs a single integrated complex: chlor-alkali. Salt goes in. Electrolysis happens. Caustic soda, chlorine, and hydrogen come out.

Caustic soda is the bread. It sells into textiles (alkali for dyes), pulp and paper (delignification), alumina refineries (bauxite processing), and soaps and detergents (saponification). It’s cheap, commodity, durable. Price moves by the week on global supply and chlorine oversupply.

Chlorine is the trap. It’s a forced co-product: you can’t make caustic without it. GACL captures some chlorine value by downstream processing into chloromethanes (CH₃Cl, CH₂Cl₂), which go into agrochemicals, pharmaceuticals, and silicon. But when chlorine prices crater—as they did in FY24—the whole unit margin collapses.

Hydrogen is the gift. It gets sold to refineries or used internally.

The company has built a portfolio: 36 products now. Hydrogen peroxide. Phosphoric acid. Aluminium chloride. Potassium carbonate. None are marquee players, but together they let GACL hedge against a single commodity crashing. When caustic prices fell, phosphoric acid and hydrogen peroxide held up better.

Capacity utilisation in FY24 was 82%. By Q4 FY26, operating profit had recovered to ₹110 crore in a single quarter, suggesting utilisation was climbing back.

The business model is efficient where it counts. GACL has invested in membrane cell technology—uses one-third less power than old mercury cells. It owns 171.45 MW of wind farms, 35 MW of solar, and a captive 90 MW gas plant. Power is 30–34% of its cost of goods sold. Self-generation cuts that cost in half.

But it’s still a commodity play. Margins compress fast when oversupply hits. The portfolio diversification helps, but not enough.

4. Financials Overview

Figures are consolidated, in ₹ crore.

FY26 revenue grew 7% despite two years of sector weakness. EBITDA more than doubled from FY25, climbing to ₹796 crore. Yet PAT remained in loss territory at ₹2 crore. The gap—EBITDA strong, profit weak—is depreciation (₹414 crore) and interest (₹63 crore). The company borrowed heavily for capex in FY22–23 and is now carrying that debt service.

Q4 FY26 was the inflection. Revenue of ₹1,125 crore (up 4.6% QoQ). Operating profit of ₹110 crore. Operating margin of 9.8%—the best quarter since